Serum Golgi protein 73 is not a suitable diagnostic marker for hepatocellular carcinoma.
Serum Golgi protein 73 is not a suitable diagnostic marker for hepatocellular carcinoma.
复制标题
DOI：
10.18632/oncotarget.14954
复制
发表时间：
2017-03-07
期刊：
影响因子：
--
通讯作者：
Lu F
中科院分区：
文献类型：
--
作者：
Liu T;Yao M;Liu S;Wang L;Wang L;Hou J;Ma X;Jia J;Zhao J;Zhuang H;Lu F
高尔基体蛋白73（GP73）已被建议作为诊断肝细胞癌（HCC）的血清标志物。然而，近年来这一点受到了挑战。在本研究中，我们发现血清GP73在肝硬化的肝癌患者中升高，而在无肝硬化的肝癌患者中不升高。受试者工作特征曲线（ROC）分析表明，血清GP 73对肝硬化患者和肝癌患者的鉴别能力较差。此外，免疫组化显示GP73的异常表达主要见于肝硬化和HCC患者的肝组织和肿瘤组织中，而很少见于无肝硬化的HCC患者的非肝组织中。肝癌合并肝硬化患者切除肿瘤组织后，血清甲胎蛋白明显下降，而血清GP73保持稳定。提示肝硬化背景与肝癌患者血清GP73水平升高有关。结论：血清GP73不是HCC的合适诊断标志物。
Golgi protein 73 (GP73) has been suggested as a serum marker for the diagnosis of hepatocellular carcinoma (HCC). However, this has been challenged in recent years. In the present study, we found that the serum GP73 increased in HCC patients with cirrhosis but not in those without cirrhosis. The receiver operating characteristic curve (ROC) analysis demonstrated that serum GP73 had poor performance for differentiating HCC patients from cirrhosis patients. In addition, the immunohistochemistry revealed that aberrant expression of GP73 was primarily observed in cirrhotic and tumor liver tissues from both cirrhosis and HCC patients, but rarely in non-cirrhotic liver tissues from HCC patients without cirrhosis. Moreover, serum Alpha-fetoprotein in HCC patients with cirrhosis decreased sharply after resection of tumor tissue, while the serum GP73 remained stable. These data indicated that the background of cirrhosis was related to the elevation of serum GP73 in HCC patients. In conclusion, serum GP73 is not a suitable diagnostic marker for HCC.